SG11201600076WA - LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME - Google Patents
LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAMEInfo
- Publication number
- SG11201600076WA SG11201600076WA SG11201600076WA SG11201600076WA SG11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA
- Authority
- SG
- Singapore
- Prior art keywords
- sirna
- double
- preventing
- composition
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130080579A KR20150006742A (en) | 2013-07-09 | 2013-07-09 | Liver cancer related genes-specific siRNA, double-stranded oligo RNA molecules comprising the siRNA, and composition for the prevention or treatment of cancer comprising the same |
PCT/KR2014/006145 WO2015005669A1 (en) | 2013-07-09 | 2014-07-09 | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201600076WA true SG11201600076WA (en) | 2016-02-26 |
Family
ID=52280271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201600076WA SG11201600076WA (en) | 2013-07-09 | 2014-07-09 | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160168573A1 (en) |
EP (1) | EP3019611A4 (en) |
JP (1) | JP2016531563A (en) |
KR (1) | KR20150006742A (en) |
CN (1) | CN105765069A (en) |
SG (1) | SG11201600076WA (en) |
WO (1) | WO2015005669A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210093654A1 (en) * | 2017-07-28 | 2021-04-01 | Lemonex Inc. | Pharmaceutical composition for preventing or treating liver cancer |
CN110964816A (en) * | 2019-11-20 | 2020-04-07 | 深圳市鲲鹏未来科技有限公司 | Solution containing blood-stable nanoparticles, preparation method thereof and detection method of miRNA marker |
CN111189808B (en) * | 2019-12-25 | 2022-12-06 | 宁夏医科大学总医院 | Screening method of specific protein molecular marker related to liver injury and hepatocyte apoptosis |
CN111596059A (en) * | 2020-05-19 | 2020-08-28 | 上海长海医院 | Application of Gankyrin protein as novel molecular marker in prostate cancer prognosis evaluation |
KR102329524B1 (en) * | 2021-08-06 | 2021-11-23 | 주식회사 네오나 | Composition for preventing or treating of liver cancer comprising modified rt-let7 as an active ingredient |
WO2023013818A1 (en) * | 2021-08-06 | 2023-02-09 | 주식회사 네오나 | Composition for prevention or treatment of liver cancer comprising modified rt-let7 as active ingredient |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2159626C (en) * | 1993-04-02 | 2001-10-02 | Lingna Li | Method for delivering beneficial compositions to hair follicles |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
EP1812494A1 (en) * | 2004-09-29 | 2007-08-01 | Alza Corporation | Microparticles and nanoparticles containing a lipopolymer |
CA2675834A1 (en) * | 2007-01-16 | 2008-07-24 | Proteologics, Ltd. | Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors |
KR101224828B1 (en) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | SiRNA conjugate and preparing method thereof |
EP2496268A4 (en) * | 2009-11-06 | 2013-06-19 | Univ Chung Ang Ind | Nanoparticle-based gene delivery systems |
ES2899043T3 (en) * | 2011-12-15 | 2022-03-09 | Bioneer Corp | Novel oligonucleotide conjugates and their use |
-
2013
- 2013-07-09 KR KR20130080579A patent/KR20150006742A/en not_active Application Discontinuation
-
2014
- 2014-07-09 JP JP2016525279A patent/JP2016531563A/en not_active Withdrawn
- 2014-07-09 CN CN201480048986.8A patent/CN105765069A/en active Pending
- 2014-07-09 EP EP14822311.8A patent/EP3019611A4/en not_active Withdrawn
- 2014-07-09 US US14/902,808 patent/US20160168573A1/en not_active Abandoned
- 2014-07-09 WO PCT/KR2014/006145 patent/WO2015005669A1/en active Application Filing
- 2014-07-09 SG SG11201600076WA patent/SG11201600076WA/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015005669A1 (en) | 2015-01-15 |
JP2016531563A (en) | 2016-10-13 |
CN105765069A (en) | 2016-07-13 |
EP3019611A4 (en) | 2017-06-14 |
KR20150006742A (en) | 2015-01-19 |
US20160168573A1 (en) | 2016-06-16 |
EP3019611A1 (en) | 2016-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3326661B8 (en) | Bio-ink composition having improved physical and biological properties | |
EP3019612A4 (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
HK1215378A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
IL243752B (en) | Multispecific antibodies, compositions comprising same and uses thereof | |
EP2861256A4 (en) | Compositions for treating cancer and methods for making the same | |
IL245281A0 (en) | Methods and compositions for treating cancer | |
BR112015001838A2 (en) | efflux inhibitor compositions and treatment methods using the same. | |
EP3018209A4 (en) | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease | |
EP2818483A4 (en) | Medicinal composition for treating and/or preventing cancer | |
EP3074391A4 (en) | Rna polymerase i inhibitors and uses thereof | |
EP3085784A4 (en) | Nucleic acid inducing rna interference modified for preventing off-target, and use thereof | |
PT3272874T (en) | Reagent composition for biosensor and biosensor having the same | |
SG11201600076WA (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
IL277261A (en) | Small molecules against cancer | |
EP3052510A4 (en) | Methods and compositions for treating and/or preventing mucositis | |
EP3085380A4 (en) | Composition for treating prostate cancer | |
IL241823B (en) | C. novyi containing compositions and uses thereof in treating solid tumors | |
EP2822998A4 (en) | Compatibilized composition, method for the formation thereof, and article comprising same | |
ZA202001649B (en) | Rna molecules | |
EP2981554A4 (en) | Methods and compositions for treating and preventing disease associated with avb8 integrin | |
EP3052122A4 (en) | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma | |
BR112015002729A2 (en) | coating composition, article, and method. | |
EP2887942A4 (en) | Compositions and methods for treating or preventing anthracycline induced cardiotoxicity | |
EP2836551A4 (en) | Compatibilized composition, method for the formation thereof, and article comprising same | |
EP3363461A4 (en) | Anti-cd43 antibody and use thereof for cancer treatment |